Register for free to
view the full innovation profile.
A vaccine that combines RSV-pre-fusion F protein and influenza M1 protein to provide effective protection against RSV infection (GSU 2017-07)
About
Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants and children worldwide. Each year, approximately 30 million acute respiratory illnesses and more than 60,000 childhood deaths are caused by RSV worldwide. In the U.S., roughly 70,000 - 120,000 infants are hospitalized annually with RSV-related pneumonia or bronchiolitis. Currently, there is no licensed vaccine, and effective therapies are not widely available. Technology: Georgia State University researchers develop virus-like particles (VLP) consisting of an influenza virus matrix (M1) protein core and an RSV unique pre-fusion conformation- stabilized fusion (F) protein on the surface. The efficiency of this construct has been tested in mice after intramuscular vaccination. Results show that RSV-pre-fusion F VLP induces significant levels of IgG antibody responses in both serum and lung. Vaccinated mice show reduced lung viral loads and decreased weight loss after challenged with live RSV-A2.
Key Benefits
RSV unique pre-fusion VLP vaccines from serum-free insect cells allow ease of culture and higher expression level May provide effective protection against RSV infection